Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Gets Bricks And Mortar Money: Last Vaccine Support From Bush Administration

This article was originally published in The Pink Sheet Daily

Executive Summary

Commercial production at North Carolina facility supported by the HHS grant is at least three years away.

You may also be interested in...



Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions

Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging

Cell-Based Vaccine Development Gives Protein Sciences The Chills; Challenges Include Getting Advisory Committees To Accept FDA Decisions

Developing a new class of medical products takes creativity and perseverance by both sponsors and regulators, but as Protein Sciences' experience shows, bringing advisory committees up to speed on novel technologies can be just as important and challenging

Flu Vaccine Funds From Gov’t Could Help Firms Upgrade Production Facilities

Federal coffers could be tapped to pay for construction or rehabilitation of privately owned vaccine production facilities under a supplemental appropriations bill passed by the House May 14

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel